NEWS


MAY 2018, Horasis Global Meeting, Cascais, Portugal

-BioLingus will speak at this Global Horasis meeting, in the section on “Spearheading economic growth”.
Read more


NOV 2017, EuroTides conference 2017 in Vienna

- BioLingus will be presenting at the EuroTides conference in Vienna on 8 NOV 2017.
Read more


SEP 2017, 17th Annual Biotech in Europe Forum(aka the Sachs conference)

- Yves Decadt, CEO of BioLingus, will be speaking at the 17th Annual Biotech in Europe Forum (aka the Sachs conference), and will be member of the diabetes and obesity panel.
Read more


JULY 2017, Two prestigious awards from CEO Monthly Magazine

- We are pleased to announce that the CEO Monthly Magazine has presented two prestigious awards to BioLingus : Best European CEO Biotech – Europe, Most Innovative Biotech company – Europe .
Read more


JUNE 2017, 2017 Horasis Meeting in Interlaken, Switzerland

- BioLingus will be presenting at the 2017 Horasis Meeting on June 25-26 in Interlaken, Switzerland.
Read more


MAY 2017, ACQ 2017 Global Awards Program

-For the second time, BioLingus has been awarded the “GAMECHANGER AWARD” in the category Biotech from the ACQ 2017 Global Awards Program.
Read more


MAY 2017, 2017 Sino-Europe BioPartnering(SEBP)conference in Shanghai

- BioLingus will be presenting at the 2017 Sino-Europe BioPartnering (SEBP) conference in Shanghai, China on 15-16 May 2017.
Read more


APR 2017, TIDES conference in April 2017 in San Diego

- BioLingus will present its technology at the TIDES conference in April 2017 in San Diego.


JAN 2017, 2016 ACQ annual awards

- BioLingus is proud to be the winner of the “Gamechanger Award” and “European Biotech Award” 2016 from the ACQ annual awards program”.
Article and Read more


NOV 2016, 2016 Business Worldwide Magazine Awards

- BioLingus CEO Scoops Two Wins in Business Worldwide Magazine Awards.
Read more


NOV 2016, Best Delivery System from the Global Health & Packaging magazine

- BioLingus wins Best Delivery System Award from the Global Health & Packaging magazine.
Read more


NOV 2016, 2016 Business Worldwide Magazine Awards

- BioLingus CEO Scoops Two Wins in Business Worldwide Magazine Awards.
Read more


NOV 2016, Biolingus article in Business Worldwide Magazine

- BioLingus Article in Business Worldwide Magazine "The non-invasive delivery of biological drugs: a holy grail in the pharmaceutical industry?"
Read more


Jan 2017, 35th Annual Healthcare Conference

- BioLingus will participate in the “J.P. Morgan 35th Annual Healthcare Conference” in January 2017 in San Francisco.


Nov 2016, 2016 Bio-Europe conference

- BioLingus will participate in the Bio-Europe conference in Germany.


Sep 2016, Wuxi Apptec and BioLingus enter into Co-Marketing Agreement

- BioLingus GmbH, based in Hergiswil, Switzerland has signed a non-exclusive co-marketing agreement with WuXi Apptec today.

Following this agreement, a percentage of the revenues from each party will be shared. Furthermore, the agreement will allow BioLingus to negotiate additional independent deals.
BioLingus is spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations, not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies etc. Biolingus’ technology is patent protected for the next 20 years. Patents have been granted in USA, Australia, China, Japan, Russia, Indonesia with Europe, Canada, Mexico, Brazil, Malaysia and Thailand to follow.

WuXi Apptec Inc.
is a publicly listed company in the US Stock Exchange.

WuXi Apptec services over 300 of the top global pharmaceutical and biotechnology companies. Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 12,000 employees and 6 million square feet of laboratory and manufacturing space, including facilities under construction.


Jul 2016, Yves Decadt, Biolingus CEO explains the innovative technology in EUROPEANCEO

- Yves Decadt, Biolingus CEO explains the innovative technology that takes injectable medicines and transforms them into pills.
Read more


Jul 2016, EUROPENCEO Interview with Yves Decadt, CEO, BioLingus

- Inspiration from nature is transforming how medicines work - EUROPENCEO Interview with Yves Decadt, CEO, BioLingus.
Read more


Jun 2016, BIO International Convention 2016

- Yves Decadt, CEO of BioLingus, will participate in 2016 BIO International Convention on June 6-9 at Moscone Center, San Francisco, California.
Read more


May 2016, 2016 European CEO Magazine Awards

- BioLingus has been selected as the winner of the 2016 award in the section "MOST INNOVATIVE BIOTECH COMPANY” from the European CEO magazine.  Awards will be presented during the 2017 WEF in Davos.
Read more


Feb 2016, Swiss-Scandinavian Bio-Business Seminar

- Yves Decadt, CEO of BioLingus, will participate in 10th Swiss-Scandinavian Bio-Business Seminar 2016 on February 10 at the SIX Swiss Exchange in Zurich.


Jan 2016, Drug Development Partnerships

- Yves Decadt, CEO of BioLingus, will participate in Drug Development Partnerships, Palm Beach Gardens, FL, United States, on 20-22 Jan 2016.


Nov 2015, Bio-Europe 2015

- Yves Decadt, CEO of BioLingus, will present at Bio-Europe 2015, Munich Germany, on 2-4 Nov 2015.


Sept 2015, Peptide Therapeutic Forum, MipTec Congress 2015

- Yves Decadt, CEO of BioLingus, will present at Peptide Therapeutic Forum, MipTec Congress 2015, Basel (CH) on 22-23 Sept 2015.


Jun 2015, Alpine High-tech Venture Forum, Lausanne

- BioLingus will participate in the Alpine High-Tech Venture Forum in Lausanne, 24-25 June 2015.


Jun 2015, Bio International Convention

- BioLingus will participate in the Bio International Convention, June 15-18, Philadelphia, USA.


May 2015, Sino-European Bio-Partnering(SEBP)

- Yves Decadt, CEO of BioLingus, will present at the at the Sino-European Bio-Partnering (SEBP) in Shanghai China on 14th May 2015.


Mar 2015, INARTIS Drug Delivery Event in Zürich

- Yves Decadt, CEO of BioLingus, will present at the INARTIS Drug Delivery Event in Zürich, 23rd March 2015.


Feb 2015, Venture Summit | West 2015

- Yves Decadt, CEO of BioLingus, will present at Venture Summit West 2015, Palo Alto, USA.


Feb 2015, 9th Swiss-Scandinavian Bio-Business Seminar

- BioLingus will participate in 9th Swiss-Scandinavian Bio-Business Seminar, 5th February 2015.


Feb 2015, Swiss HLG Winter Conference

- BioLingus will participate in Swiss HLG Winter Conference, Flims February 2015.


Nov 2014, Bio-Europe Partnering conference in Frankfurt

- BioLingus will participate in Bio-Europe Partnering conference in Frankfurt, Germany.


Oct 2014, Biolingus drug delivery patent has been granted in USA in addition to Australia

- Message from the CEO : "I am happy to communicate that this month, our drug delivery patent WO2012/109694 A1 has been granted in USA in addition to Australia. This is an important step in the strengthening of our patent portfolio for the most important pharmaceutical territory, which is still USA. We are confident that other important territories will follow. This also demonstrate our company with our breakthrough technology is able to deliver real novelty, to change the way how peptides and proteins are administered in the future. With this, I want to especially thank Mr. Thomas Ko, who is the key inventor of this patent and also CTO of BioLingus."


Oct 2014, The 11th Swiss CEO day in Bern, Switzerland

- Yves Decadt, CEO of BioLingus, will participate in the 11th Swiss CEO day in Bern, Switzerland.


Sept 2014, The 14th Annual Biotech in Europe Forum

- Yves Decadt, CEO of BioLingus, will present at the 14th Annual Biotech in Europe Forum, 30th September - 1st October 2014, Basel Congress Centre, Switzerland.


Jun 2014, 2014 BIO International Convention

- BioLingus will participate in the Bio Conference in San Diego, 23-36 June 2014.


Jun 2014, BIT"s 1st Annual Global Innovation Economic Congress

- Yves Decadt, CEO of BioLingus and Tom Ko, CTO of BiolLingus are invited as speaker on Bit congress forum 1013&1015 from June 26-29 2014.


Mar 2014, 7th Annual European Life Science CEO Forum in Zurich

- Yves Decadt, CEO of BioLingus, will present at the 7th Annual European Life Science CEO Forum taking place on 4th-5th March 2014 at Hilton Zurich Airport Hotel.


Feb 2014, Swiss Healthcare Licensing Conference

- We participate in the Swiss Healthcare Licensing Conference in Flims (Switzerland), from February 2-4.


Jan 2014, Drug Delivery Partnership conference in Miami

- Yves Decadt, CEO of BioLingus, will present in January 2014 on the Drug Delivery Partnership conference in Miami.


Jan 2014, JP Morgan Health conference in San Francisco

- We participate in the JP Morgan Health conference in San Francisco mid January




July 2016
Yves Decadt, Biolingus CEO explains the innovative technology that takes injectable medicines and transforms them into pills.
Read more


RECENT NEWS


JUL 2017
Two prestigious awards from CEO Monthly Magazine
Best European CEO Biotech – Europe
Most Innovative Biotech company – Europe
Read more


NOV 2016
BioLingus wins Best Delivery System Award from the Global Health & Packaging magazine. .
Read more


NOV 2016
BioLingus CEO Scoops Two Wins in Business Worldwide Magazine Awards.
Read more


MAY 2016
BioLingus has been selected as the winner of the 2016 award in the section "MOST INNOVATIVE BIOTECH COMPANY” from the European CEO magazine.  Awards will be presented during the 2017 WEF in Davos.
Read more


July 2016
Inspiration from nature is transforming how medicines work - EUROPENCEO Interview with Yves Decadt, CEO, BioLingus.
Read more


Contacts

 



Main Office
BioLingus AG

Grossmatt 6
CH-6052 Hergiswil NW
Switzerland
Email
info@biolingch.ch